This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aqeilan, R. I. Articles by Croce, C. M. Search for Related Content PubMed PubMed Citation Articles by Aqeilan, R. I. Articles by Croce, C. M.

WW Domain–Containing Proteins, WWOX and YAP, Compete for Interaction with ErbB-4 and Modulate Its Transcriptional Function

¹ Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; ² Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania; and ³ Department of Medicine, Mt. Sinai School of Medicine, New York, New York

Requests for reprints: Rami I. Aqeilan, Department of Human Cancer Genomics, The Ohio State University, Room 455E, Wiseman Hall, 410 West 12th Avenue, Columbus, OH 43220. Phone: 614-292-3120; Fax: 614-292-4053; E-mail: rami.aqeilan{at}osumc.edu.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The WW domain–containing oxidoreductase, WWOX, is a tumor suppressor that is deleted or altered in several cancer types. We recently showed that WWOX interacts with p73 and AP-2 and suppresses their transcriptional activity. Yes-associated protein (YAP), also containing WW domains, was shown to associate with p73 and enhance its transcriptional activity. In addition, YAP interacts with ErbB-4 receptor tyrosine kinase and acts as transcriptional coactivator of the COOH-terminal fragment (CTF) of ErbB-4. Stimulation of ErbB-4–expressing cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) results in the proteolytic cleavage of its cytoplasmic domain and translocation of this domain to the nucleus. Here we report that WWOX physically associates with the full-length ErbB-4 via its first WW domain. Coexpression of WWOX and ErbB-4 in HeLa cells followed by treatment with TPA results in the retention of ErbB-4 in the cytoplasm. Moreover, in MCF-7 breast carcinoma cells, expressing high levels of endogenous WWOX, endogenous ErbB-4 is also retained in the cytoplasm. In addition, our results show that interaction of WWOX and ErbB-4 suppresses transcriptional coactivation of CTF by YAP in a dose-dependent manner. A mutant form of WWOX lacking interaction with ErbB-4 has no effect on this coactivation of ErbB-4. Furthermore, WWOX is able to inhibit coactivation of p73 by YAP. In summary, our data indicate that WWOX antagonizes the function of YAP by competing for interaction with ErbB-4 and other targets and thus affect its transcriptional activity.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Gene expression can be regulated through a variety of mechanisms including the modulation of transcription factor localization (1). Transcription factors may associate with different cofactors that may repress or enhance their transcriptional activity. Modulation of subcellular localization of transcription factors in the nucleus or cytoplasm plays an important role in the integration of signal transduction and control of transcriptional machinery (1). Recently, we showed that WW domain–containing oxidoreductase (WWOX) functions as a regulator of subcellular localization of p73 and AP2 transcription factors (2, 3). WWOX inhibits nuclear translocation of p73 and AP2 hence suppressing their transactivating ability.

WWOX was originally cloned as a putative tumor suppressor gene that spans one of the most common active fragile sites in the human genome, FRA16D (4–6). WWOX is located on chromosome 16q23.3 and exhibits genomic alterations in several cancer types (7) and a recent study showed a possible involvement of methylation in the regulation of WWOX expression (8). WWOX expression is frequently altered in tumor tissues (9–13) and introduction of WWOX into WWOX-negative tumor cells resulted in tumor suppression and apoptosis (10, 14). The tandem WW domains of WWOX (Fig. 1A) play an important role in WWOX function. Both WW domains of WWOX contain the central core of two consecutive aromatic amino acids and therefore belong to the class I specificity of domains, which recognize ligands with the PPxY consensus motif (where P is proline, Y is tyrosine, and x is any amino acid; refs. 2, 15–19). Recent mapping of the WW domain in the human proteome identified a repertoire of PPxY-containing ligands that bind to individual domains of WWOX (20). The first WW of WWOX bound 18 and the second WW bound 16 ligands, all with PPxY consensus. The mapping data clearly documented that although the second WW domain of WWOX contains a tyrosine in the place of the second conserved tryptophan, the signature residue directly involved in ligand binding (21), the specificity of the "WY domain" toward PPxY core was not changed (20).

View larger version (24K): [in this window] [in a new window]   Figure 1. Schematic illustration of WWOX and ErbB-4 proteins. A, structure of full-length of human WWOX. WWOX contains two WW domains and short dehydrogenase domain (SDR). Myc-WWOX, Myc-WWOXY33R, and WWOX-GFP constructs were used to express WWOX protein. B, structure of human YAP. There are two YAP isoforms. YAP2 contains two WW domains compared with one WW domain in YAP1 but both share the same Akt phosphorylation site and transcription activation domain. C, structure of human ErbB-4. All isoforms of ErbB-4 contain cysteine-rich domains, domains I to IV in the ectodomain, transmembrane region (TM), and the tyrosine kinase domain. In the CYT-2 isoform, the PI3K-binding motif is deleted. There are three PPxY motifs that are possible binding sequences for the class I WW domains. The second PPxY motif is included in the PI3K binding domain site that is deleted in the CYT-2 isoform. The COOH-terminal fragment (residues, 676-1292) that is known to translocate to the nucleus is indicated as CTF. CTF-K (residues, 988-1292) lacks the tyrosine kinase domain but still have better transactivation ability than CTF.

Recently, YAP was shown to interact with ErbB-4 receptor acting as a transcriptional coactivator of the COOH terminus domain of ErbB-4 (28, 30). The HER4/ERBB4 gene is a member of type I receptor tyrosine kinase subfamily that includes epidermal growth factor receptor ERBB1, ERBB2, and ERBB3 (reviewed in ref. 31). ErbB-4 regulates cell proliferation and differentiation (32). After binding its ligand heregulin or following the activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA), the ErbB-4 ectodomain is cleaved by a metalloprotease tumor necrosis factor-–converting enzyme followed by -secretase cleavage (33). The cleavage by -secretase facilitates the translocation of the COOH-terminal fragment of ErbB-4 (CTF) to the nucleus where it may affect the transcription of target genes (34). CTF by itself does not possesses transactivating activity; however, in the presence of YAP, its transcriptional activity is revealed (28, 30). Different isoforms of ErbB-4 were previously described (Fig. 1C). JM-a isoform is sensitive to cleavage, whereas the JM-b isoform is insensitive to the cleavage because of the sequence difference in the juxtamembrane region (35). CYT-1 and CYT-2 are two other isoforms of ErbB-4. CYT-1 contains a binding motif for the phosphatidylinositol 3-kinase (PI3K), whereas CYT-2 lacks this sequence (36, 37).

Because WWOX and YAP have the similar tandems of WW domains and interact with common protein targets but have different effects on transactivation, we decided to investigate whether WWOX and YAP expression have opposite effects on their target proteins. Here we report that WWOX physically associate with the cytoplasmic region of ErbB-4 via its first WW domain and suppresses transactivation activity of ErbB-4 mediated by YAP.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell culture and transient transfection. Human HEK293, HeLa, and MCF-7 cells were grown in RPMI supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and Gentamicin. Cells were maintained at 37°C in a water saturated atmosphere of 5% CO₂ in air. Overexpression of proteins was achieved by transient transfections using FuGENE 6 transfection reagent, according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN).

Plasmid construction. The mammalian expression plasmids encoding MYC epitope-tagged WWOX and pCMV-MYC-WWOXY33R were previously described (ref. 2; Fig. 1A). An additional Myc Tag was added in 3' terminus of both WWOX constructs. Full-length WWOX cDNA was cloned into a pEGFP-N1 vector (Clontech, Palo Alto, CA). Full-length cDNA of YAP2 were cloned into a pCDNA4-HisMaxB vector (Omni-YAP2; Invitrogen) using standard protocols (Fig. 1B). Full-length ErbB-4 with COOH-terminal HA epitope tag, ErbB-4 CTF, and CTF lacking the kinase domain (CTF-K) were previously described (ref. 28; Fig. 1C). Full-length ErbB-4PY1-HA, ErbB-4PY3-HA and ErbB-4Py1,3-HA mutants were generated using Site Directed Mutagenesis kit (Stratagene, La Jolla, CA) according to manufacturer's instructions. The reporter plasmid pFR-luc expressing Firefly luciferase and contains a synthetic promoter with five tandem repeats of the yeast GAL4-binding sites and pTK-RL expressing Renilla luciferase as an internal control were purchased from Stratagene and Promega (Madison, WI), respectively. The reporter p53RE-Luc (Stratagene) carrying the p53-responsive element derived from p53 promoter was used to assay p73 transactivation.

Immunoprecipitation and immunoblot analysis. Cells were lysed and immunoprecipitations were carried out as previously described (2). Antibodies used were mouse monoclonal anti-HA (Covance, Princeton, NJ), mouse monoclonal anti-Omni (Santa Cruz Biotechnology), mouse monoclonal anti-Myc (Zymed, South San Francisco, CA) and mouse monoclonal anti-WWOX (10). Antibodies used for immunoblot were anti-HA-horseradish peroxidase (HRP, Roche Diagnostics), anti-Myc-HRP, and mouse monoclonal anti-Omni (Santa Cruz Biotechnology).

Immunofluorescence. Cells were seeded on fibronectin-covered cell culture slides (Becton Dickinson, San Jose, CA). HeLa cells were transfected with expression vectors encoding WWOX-GFP, Omni-YAP2, and ErbB-4-HA using FuGENE 6 (Roche Diagnostics). After 24 hours, cells were treated with TPA (100 ng/mL) or DMSO for 90 minutes and then cells were prepared as previously described (2). MCF-7 cells were treated with TPA and prepared as above. Antibodies used were mouse monoclonal anti-HA (Covance), rabbit polyclonal anti-ErbB-4 (Santa Cruz Biotechnology), mouse monoclonal anti- WWOX, anti-Rabbit Flouro-conjugated antibody and anti-mouse Texas red–conjugated antibody (Invitrogen). Cells were visualized using Zeiss LCM 510 confocal microscope.

Luciferase assays. In these experiments, we mainly used the CTF isoform that lacks kinase domain (CTF-K) because it shows a better transactivation activity when compared with the entire CTF (28, 33). We also used pFR-luc reporter construct (Stratagene) containing five copies of Gal4 DNA binding sequences. 293 cells in 6-well dishes were transfected with the plasmids indicated in the figure legends using FuGENE 6 transfection reagent. Cells were collected 24 hours later and Firefly and Renilla luciferase activities were assayed with the Dual Luciferase Assay Reporter System (Promega). All experiments were done at least thrice.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
WWOX associates physically with ErbB-4. Because the WW domain–containing protein YAP associates physically and functionally with ErbB-4, we decided to investigate whether WWOX also interacts with ErbB-4 through its WW domains. We did coimmunoprecipitation experiments to assess this interaction. In all immunoprecipitation experiments, we used HA-tagged CYT-2 isoform of the full-length ErbB-4 that lacks the PI3K-binding motif (Fig. 1C). We transiently cotransfected 293 cells with constructs expressing ErbB-4-HA and Myc-WWOX and cell lysates were immunoprecipitated with anti-HA or anti-Myc antibody followed by immunoblotting with HRP-conjugated anti-HA or anti-Myc antibodies. As shown in Fig. 2A, we were able to detect immune complexes between ErbB-4 and WWOX in vivo (lane 2, top and lane 4, bottom). As a control, there were no detectable complexes in anti-IgG immunoprecipitates (Fig. 2A, lanes 3 and 6). To determine whether this interaction is mediated by the first WW domain of WWOX, we generated a mutated form of WWOX in which the conserved Tyr³³ (Y33) was substituted to arginine (R), WWOXY33R. The Y33 is located within the central core of consecutive aromatics of the WW domain and was shown to be a site of phosphorylation that regulates signaling of WWOX (2, 6). This Y-R mutation abolished interaction between WWOX and p73 or AP2 proteins (2, 3) and at the molecular level it could be explained as a substitution that compromises the "aromatic cradle" structure that is essential for the formation of WW domain-ligand complexes (38). Similarly, the WW domain mutation in WWOX completely inhibited its binding to ErbB-4 (Fig. 2A, lanes 5, top and lane 7, bottom). These results indicate that the first WW domain of WWOX is primarily responsible for the interaction with ErbB-4.

View larger version (45K): [in this window] [in a new window]   Figure 2. WWOX binds ErbB-4 via its first WW domain. A, 293 cells were transiently transfected with the expression plasmids encoding ErbB-4-HA and Myc-WWOX or Myc-WWOXY33R. Twenty-four hours after transfection, whole cell lysates were immunoprecipitated (IP) with anti-Myc (lanes 2 and 5), anti-IgG (lanes 3 and 6), or anti-HA (lanes 4 and 7) antibodies. The immunoprecipitates were analyzed by immunoblotting (IB) with anti-HA (top) or anti-Myc (bottom)-HRP–conjugated antibodies. Lanes 1 and 8, lysate expression of ErbB-4 (top) and WWOX (bottom). B, 293 cells were transiently cotransfected with the expression plasmids encoding Myc-WWOX and ErbB-4-PY1-HA or ErbB-4-PY3-HA. Immunoprecipitation were as follows: anti-HA (lanes 2 and 5), anti-IgG (lanes 3 and 6), or anti-Myc (lanes 4 and 7) and immunoblotting were as in (A). Lanes 1 and 8, expression of ErbB-4 (top) and WWOX (bottom). C, 293 cells were transiently cotransfected with the expression plasmids encoding Myc-WWOX and ErbB-4-HA or ErbB-4-PY1,3-HA. Immunoprecipitation and immunoblotting were as in (B).

WWOX and ErbB-4 colocalize in the cytoplasm. We next examined the effect of WWOX-ErbB-4 interaction on the subcellular localization of WWOX and ErbB-4. To address this, we studied the localization of both proteins with the aid of confocal microscopy. ErbB-4 receptor has a cytoplasmic domain that translocates to the nucleus following stimulation with TPA (33). To examine the effect of WWOX-ErbB-4 association on this step of signaling in our experimental system, ErbB-4-HA alone or with WWOX-GFP was transiently expressed in HeLa cells. Localization of the HA-tagged proteins was then determined by immunofluorescent staining, as described in Materials and Methods. As shown in Fig. 3A, ErbB-4 alone localizes in the cell membrane and cytoplasm, whereas WWOX is mainly in the cytoplasm (Fig. 3A, b and a). Coexpression of WWOX-GFP and ErbB-4-HA resulted in partial colocalization of WWOX and ErbB-4 in the cytoplasm (Fig. 3A, c). Figure 3A (bottom) shows translocation of CTF into the nucleus following treatment with TPA; however, localization of WWOX-GFP was not affected (Fig. 3A, e and d). By contrast, cells coexpressing WWOX and ErbB-4 and treated with TPA showed a cytoplasmic colocalization of both proteins (Fig. 3A, f). These results indicate that expression of WWOX causes retention of CTF in the cytoplasm and prevents its translocation to nucleus. To show this effect on endogenous proteins, we used MCF-7 breast carcinoma cells that express high levels of endogenous WWOX and moderate levels of endogenous ErbB-4. We used confocal microscopy and localization of endogenous proteins was then determined by immunofluorescent staining using polyclonal antibody against ErbB-4 (Santa Cruz Biotechnology) and our monoclonal antibody against WWOX (10). As expected, MCF-7 cells express both ErbB-4 and WWOX in the cytoplasm (Fig. 3B, a-b). Treatment of MCF-7 cells with TPA resulted in partial translocation of CTF into the nucleus (Fig. 3B, c-d). Interestingly, cells displaying nuclear CTF have significantly reduced expression of WWOX (Fig. 3B, d), which might explain this partial sequestration of endogenous ErbB-4. However, we cannot exclude that there might be other factor(s) regulating ErbB-4 translocation into nucleus. Altogether, our results suggest that WWOX binds ErBb-4 in the cytoplasm and prevents CTF translocation to the nucleus.

View larger version (42K): [in this window] [in a new window]   Figure 3. Subcellular localization of WWOX and ErbB-4. A, HeLa cells were transfected with the indicated plasmids. Twenty-four hours later, cells (d-f) were treated with TPA (100 ng/mL) for 90 minutes. Cells then were fixed and permeabilized and immunostained with anti-HA antibodies followed by Texas red–conjugated anti-mouse IgG (red, CTF). Colocalization of WWOX and CTF is in yellow as a result of colors merging. B, MCF-7 cells were treated with TPA (100 ng/mL) for 90 minutes (c-d). Cells were prepared as in (A). Antibodies used were polyclonal anti-ErbB-4 (green) and monoclonal anti-WWOX (red). All cells were visualized by confocal microscopy using x63 objective lens.

View larger version (26K): [in this window] [in a new window]   Figure 4. A, association of WWOX-ErbB-4 suppresses transactivation of CTF mediated by YAP. 293 cells were cotransfected with the Gal4DNA binding domain (Gal4BD, residues 1-142) fused to the CTF-K fragment (residues 988-1292) and with pFR-luc (0.3 µg), Omni-YAP2 (0.2 µg), Omni-YAP2-1stWW* [mYAP2] (0.2 µg), Myc-WWOX (0.1-0.3 µg), and Myc-WWOXY33R [mWWOX] (0.2-0.3 µg) as indicated. Empty vector was cotransfected to normalize DNA amount where required. A reporter plasmid encoding Renilla luciferase was also cotransfected to normalize transfection efficiencies. Twenty-four hours posttransfection, cells were lysed and luciferase activity was determined. Results are shown as fold activation of the luciferase activity compared with control cells transfected with empty vector alone. Columns, averages of three experiments. B, HeLa cells were transfected with constructs expressing CTF-K alone or together with WWOX-GFP. Cells were immunostained with polyclonal anti-ErbB-4 (red) and visualized as in Fig. 3. C, WWOX suppresses transactivation of p73 mediated through p73-YAP association. 293 cells were cotransfected with vectors expressing p53RE-Luc (0.1 µg), HA-p73ß (10 ng), Omni-YAP2 (0.2 µg), Myc-WWOX (0.5 µg), and Nuc-WWOX-Myc (0.5 µg) as indicated. Cells were then treated as in (A). D, HeLa cells were transfected with pCMV-NUC-WWOX-MYC plasmid. Twenty-four hours later, cells were incubated with MitoTracker Red (red, mitochondria) and immunostained with anti-Myc antibodies followed by FITC-conjugated anti-mouse IgG (green, WWOX). Cells were visualized as in Fig. 3.

CTF-K

Because it was shown that YAP could serve as a coactivator of p73 (25), we decided to check the effect of WWOX expression on this transactivation. We previously showed that WWOX suppresses p73-mediated transactivation (2). To assess the antagonizing effect of WWOX on YAP function further, we used the previously described construct containing the luciferase gene driven by a p53 cis-element from the p53 promoter (p53RE-Luc) that can be used in p73ß transactivation studies (2). As expected, p73ß showed significant transactivation of luciferase reporter and expression of YAP2 increased this effect (Fig. 4C, columns 2 and 6). By contrast, expression of p73ß and WWOX significantly suppressed the transactivation function of p73 (Fig. 4C, column 7). In addition, coexpression of YAP2, p73ß, and WWOX resulted in the suppression of p73 transactivation function (Fig. 4C, column 8) indicating that WWOX indeed antagonizes YAP function.

We previously showed that WWOX sequesters p73 in the cytoplasm explaining WWOX suppressive effect of p73 transactivation (2). To further confirm that the effect of WWOX is due to the interaction with p73 and not solely to WWOX-p73 colocalization in the cytoplasm, we constructed a myc-tagged-nuclear WWOX expression vector, named Nuc-WWOX-Myc, expressing WWOX exclusively in the nucleus (Fig. 4D). Coexpression of Nuc-WWOX and p73ß had the same suppressive effect on p73 transactivation as wild-type WWOX (Fig. 4C, column 9). Furthermore, expression of YAP2 did not affect this suppression (Fig. 4C, column 10) suggesting that the effect of WWOX expression is superior to that of YAP. Similar results were seen for the CTF-YAP2 and Nuc-WWOX complex (data not shown). This suggests that even when WWOX is in the nucleus together with p73 or CTF, it still inhibits its association with YAP and thus prevents its coactivation.

WWOX and YAP compete for interaction with ErbB-4. Our results may also suggest that WWOX and YAP compete for interaction with ErbB-4 and modulate its transactivation activity. To check whether YAP and WWOX compete for interaction with ErbB-4, we cotransfected 293 cells with fixed amounts of vectors expressing ErbB-4-HA and Myc-WWOX and variable amounts of Omni-YAP2. Cell lysates were then immunoprecipitated with anti-WWOX or anti-Omni antibodies and immunoblotted with anti-HA antibody. Our results show that in the presence of reduced amount of YAP2, ErbB-4 interacts exclusively with WWOX (Fig. 5A, lane 4 versus 5). On the other hand, increased expression of YAP2 causes some ErbB-4-YAP2 association, although ErbB-4-WWOX interaction was still the predominant complex (Fig. 5A, lane 9 versus 8). To show that WWOX expression indeed interfered with the formation of YAP-ErbB-4 complex, we cotransfected 293 cells with ErbB-4-HA, Omni-YAP2, and either Myc-WWOX or Myc-WWOXY33R. In this context, expression of Myc-WWOXY33R resulted in significant rescue of ErbB-4-YAP2 interaction (Fig. 5B, lane 9 versus 8). Altogether, our results from the Gal4 transactivation assay (Fig. 4A) and immunoprecipitation experiments (Fig. 5) indicate that WWOX and YAP may compete for the association with ErbB-4 and that WWOX-ErbB-4 interaction is prevalent.

View larger version (47K): [in this window] [in a new window]   Figure 5. WWOX and YAP compete for interaction with ErbB-4. A, 293 cells were transiently transfected with the expression plasmids encoding ErbB-4-HA (6.0 µg), Myc-WWOX (7.0 µg), and Omni-YAP2 (1.0 or 2.0 µg). Twenty-four hours after transfection, whole cell lysates were immunoprecipitated (IP) with anti-HA (lanes 2 and 6), anti-IgG (lanes 3 and 7), anti-WWOX (lanes 4 and 8), or anti-Omni (lanes 5 and 9) antibodies. The immunoprecipitates were analyzed by immunoblotting (IB) with anti-HA antibody (top). Lanes 1 and 10, expression of ErbB-4; bottom, expression of Myc-WWOX (left) and Omni-YAP2 (right). B, 293 cells were transiently transfected with the expression plasmids encoding ErbB-4–HA (6.0 µg), Omni-YAP2 (1.0 µg), and Myc-WWOX (7.0 µg) or Myc-WWOXY33R (7.0 µg). Cells were then treated as (A).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

YAP is another WW domain–containing protein that functions as a modulator of several transcription factors. YAP has been characterized as a cotransactivator for several transcription factors including the Runx family proteins, the TEAD/TEF family of transcription factors, and p73 (24, 25, 41). YAP activity typically involves either of the two WW domains that associate directly with PPxY motifs within the transcription factors, although other mechanisms of interaction may occur. Although YAP can modulate the activity of multiple transcription factors, several reports suggest that it localizes predominantly to the cytoplasm. In the cytoplasm YAP interacts with EBp50 (ezrin/radixin/moesin-binding phosphoprotein of 50 kDa), 14-3-3 and Yes protein tyrosine kinase (22, 29, 42). Most recently, it was shown that 14-3-3 interacts with YAP phosphorylated at Ser¹²⁷ and that it prevents YAP from translocation into the nucleus (29). In our study, we used the alternatively spliced CYT-2 isoform of ErbB-4 that lacks the PI3K binding motif; therefore, Akt is not activated to phosphorylate YAP at Ser¹²⁷; thus, YAP is retained in the cytoplasm. The subcellular localization of YAP and WWOX in the cytoplasm makes them accessible to bind the PPxY motif of ErbB-4. Our results imply that WWOX binds ErbB-4 in the cytoplasm and makes it inaccessible for interaction with YAP. Therefore, it is possible that WWOX binds CTF and prevents its interaction with YAP; thus, CTF cannot translocate to the nucleus where it may transactivate target genes. A mutated form of WWOX, WWOXY33R, does not bind ErbB-4; therefore, when coexpressed with YAP, it does not prevent YAP from association with ErbB-4 and transcriptional coactivation of the nucleus translocated ErbB4-YAP complex. Interestingly, WWOX binds ErbB-4 with better affinity than YAP, perhaps due to the interaction of WWOX with both the PPxY motifs of ErbB-4 rather than only with the most COOH-terminal PPxY sequence in the case of YAP-ErbB-4 association (28).

The functional importance of CTF translocation to the nuclear compartment is not yet clear. However, the fact that CTF was detected in the nucleus in different tissues and expression of nuclear CTF was reported in a number of tumors may indicate an important role of this localization. Both the Notch receptor and Alzheimer's precursor protein, are similarly cleaved by -secretase and their intracellular fragments translocate to the nucleus and directly regulate transcription of different genes (reviewed in ref. 43). Moreover, the founding member of the epidermal growth factor receptor family, ErbB-1 has been shown to bind the cyclin D1 promoter and possibly to transactivate genes essential for proliferation (44). In addition, ErbB-1 has been proposed to function as a carrier for signal transducers and activators of transcription 3 to the nuclear compartment (45). It is thus quite possible that ErbB4-CTF can transactivate target genes in the nucleus or that it functions as a shuttle protein for different targets destined for the nucleus (e.g., YAP; refs. 28, 31). Our findings show that in the presence of WWOX, CTF is retained in the cytoplasm; thus, CTF cannot transactivate target genes or shuttle proteins into the nucleus.

Recently, we showed that WWOX binds p73 transcription factor and suppresses its transcriptional function (2). Interestingly, YAP, via its WW domain also associates with p73 and this interaction causes the enhanced transcriptional activity of p73 (25). When coexpressed with YAP and p73, WWOX was able to reverse this effect. These results suggest that WWOX acts as a transcriptional corepressor antagonizing the function of YAP. A proposed model is shown in Fig. 6, where both WW domain–containing proteins, YAP and WWOX, in the cytoplasm are competing for interaction with PPxY-containing target proteins. Whereas WWOX inhibits nuclear translocation of target proteins, YAP translocates with these targets into the nucleus thus determining the transcriptional outcome of these target proteins.

View larger version (23K): [in this window] [in a new window]   Figure 6. A proposed model of WWOX and YAP function competing for interaction with ErbB-4 and other target proteins. In this model, ErbB-4-CTF is cleaved following binding of its ligand heregulin or activation of PKC with TPA. CTF by itself or together with YAP translocates to the nucleus and transactivate target genes in the nucleus. In the presence of WWOX, CTF is sequestered in the cytoplasm and transactivation is suppressed. WWOX also interact with other transcription factors such as p73 and AP-2 and inhibit their translocation to the nucleus hence suppressing their transactivation activity.

	Acknowledgments

 
Grant support: NIH grants CA77738 (C.M. Croce) and DK62345 (M. Sudol).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	Footnotes

 
⁴ Our results also confirm the in vitro data of WW domain mapping generated by AxCell Biosciences/Cytogen Corporation (20). Their protein-array data clearly showed that all three PPxYs of ErbB4 formed complexes with WWOX.

Received 4/ 4/05. Revised 5/24/05. Accepted 5/25/05.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003;282:59–69.[CrossRef][Medline]
2. Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004;101:4401–6.[Abstract/Free Full Text]
3. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2 transcription factor. Cancer Res 2004;64:8256–61.[Abstract/Free Full Text]
4. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140–5.[Abstract/Free Full Text]
5. Ried K, Finnis M, Hobson L, et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000;9:1651–63.[Abstract/Free Full Text]
6. Chang NS, Doherty J, Ensign A, et al. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol 2003;66:1347–54.[CrossRef][Medline]
7. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001;98:11417–22.[Abstract/Free Full Text]
8. Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005;24:1625–33.[CrossRef][Medline]
9. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002;62:2258–60.[Abstract/Free Full Text]
10. Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004;10:2459–65.[Abstract/Free Full Text]
11. Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004;10:3053–8.[Abstract/Free Full Text]
12. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605–14.[CrossRef][Medline]
13. Nunez MI, Ludes-Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 2005;89:99–105.[CrossRef][Medline]
14. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068–73.[Abstract/Free Full Text]
15. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A 1995;92:7819–23.[Abstract/Free Full Text]
16. Sudol M. From Src Homology domains to other signaling modules: proposal of the ‘protein recognition code’. Oncogene 1998;17:1469–74.[CrossRef][Medline]
17. Sudol M, Hunter T. NeW wrinkles for an old domain. Cell 2000;103:1001–4.[CrossRef][Medline]
18. Aasland R, Abrams C, Ampe C, et al. Normalization of nomenclature for peptide motifs as ligands of modular protein domains. FEBS Lett 2002;513:141–4.[CrossRef][Medline]
19. Ludes-Meyers JH, Kil H, Bednarek AK, Drake J, Bedford MT, Aldaz CM. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 2004;23:5049–55.[CrossRef][Medline]
20. Hu H, Columbus J, Zhang Y, et al. A map of WW domain family interactions. Proteomics 2004;4:643–55.[CrossRef][Medline]
21. Macias MJ, Hyvonen M, Baraldi E, et al. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature 1996;382:646–9.[CrossRef][Medline]
22. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994;9:2145–52.[Medline]
23. Bork P, Sudol M. The WW domain: a signalling site in dystrophin? Trends Biochem Sci 1994;19:531–3.[CrossRef][Medline]
24. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999;18:2551–62.[CrossRef][Medline]
25. Strano S, Munarriz E, Rossi M, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164–73.[Abstract/Free Full Text]
26. Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004;23:790–9.[CrossRef][Medline]
27. Sudol M, Bork P, Einbond A, et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995;270:14733–41.[Abstract/Free Full Text]
28. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003;278:33334–41.[Abstract/Free Full Text]
29. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003;11:11–23.[CrossRef][Medline]
30. Omerovic J, Puggioni EM, Napoletano S, et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 2004;294:469–79.[CrossRef][Medline]
31. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66–77.[CrossRef][Medline]
32. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.[CrossRef][Medline]
33. Ni CY, Murphy MP, Golde TE, Carpenter G. -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179–81.[Abstract/Free Full Text]
34. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 2003;15:143–8.[CrossRef][Medline]
35. Elenius K, Corfas G, Paul S, et al. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 1997;272:26761–8.[Abstract/Free Full Text]
36. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999;18:2607–15.[CrossRef][Medline]
37. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000;275:8641–9.[Abstract/Free Full Text]
38. Huang X, Poy F, Zhang R, Joachimiak A, Sudol M, Eck MJ. Structure of a WW domain containing fragment of dystrophin in complex with ß-dystroglycan. Nat Struct Biol 2000;7:634–8.[CrossRef][Medline]
39. Sudol M. Structure and function of the WW domain. Prog Biophys Mol Biol 1996;65:113–32.[Medline]
40. Sudol M. WW domain. In: Cesareni G, Gimona M, Sudol M, Yaffe M, editors. Molecular protein domains. Wiley VCH, Verlang Gmbh & Co.; 2004. p. 59–72.
41. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001;15:1229–41.[Abstract/Free Full Text]
42. Mohler PJ, Kreda SM, Boucher RC, Sudol M, Stutts MJ, Milgram SL. Yes-associated protein 65 localizes p62(c-Yes) to the apical compartment of airway epithelia by association with EBP50. J Cell Biol 1999;147:879–90.[Abstract/Free Full Text]
43. Fortini ME. -Secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 2002;3:673–84.[CrossRef][Medline]
44. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802–8.[CrossRef][Medline]
45. Bild AH, Turkson J, Jove R. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J 2002;21:3255–63.[CrossRef][Medline]
46. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.[CrossRef][Medline]
47. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483–7.[Abstract/Free Full Text]
48. Dong G, Loukinova E, Smith CW, Chen Z, Van Waes C. Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl 1997;28–29:90–100.
49. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:10384–93.

This article has been cited by other articles:

				R. I. Aqeilan, M. Q. Hassan, A. de Bruin, J. P. Hagan, S. Volinia, T. Palumbo, S. Hussain, S.-H. Lee, T. Gaur, G. S. Stein, et al. The WWOX Tumor Suppressor Is Essential for Postnatal Survival and Normal Bone Metabolism J. Biol. Chem., August 1, 2008; 283(31): 21629 - 21639. [Abstract] [Full Text] [PDF]

				C.-P. Chuu, R.-Y. Chen, J. L. Barkinge, M. F. Ciaccio, and R. B. Jones Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective Mol. Cancer Res., June 1, 2008; 6(6): 885 - 891. [Abstract] [Full Text] [PDF]

				M. Sundvall, A. Korhonen, I. Paatero, E. Gaudio, G. Melino, C. M. Croce, R. I. Aqeilan, and K. Elenius Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms PNAS, March 18, 2008; 105(11): 4162 - 4167. [Abstract] [Full Text] [PDF]

				G. Guler, D. Iliopoulos, N. Guler, C. Himmetoglu, M. Hayran, and K. Huebner Wwox and Ap2{gamma} Expression Levels Predict Tamoxifen Response Clin. Cancer Res., October 15, 2007; 13(20): 6115 - 6121. [Abstract] [Full Text] [PDF]

				R. I. Aqeilan, V. Donati, E. Gaudio, M. S. Nicoloso, M. Sundvall, A. Korhonen, J. Lundin, J. Isola, M. Sudol, H. Joensuu, et al. Association of Wwox with ErbB4 in Breast Cancer Cancer Res., October 1, 2007; 67(19): 9330 - 9336. [Abstract] [Full Text] [PDF]

				J. Omerovic, L. Santangelo, E. M.-R. Puggioni, J. Marrocco, C. Dall'Armi, C. Palumbo, F. Belleudi, L. Di Marcotullio, L. Frati, M.-R. Torrisi, et al. The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation FASEB J, September 1, 2007; 21(11): 2849 - 2862. [Abstract] [Full Text] [PDF]

				H. R. Qin, D. Iliopoulos, T. Nakamura, S. Costinean, S. Volinia, T. Druck, J. Sun, H. Okumura, and K. Huebner Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling Mol. Cancer Res., September 1, 2007; 5(9): 957 - 965. [Abstract] [Full Text] [PDF]

				A. Oberst, M. Malatesta, R. I. Aqeilan, M. Rossi, P. Salomoni, R. Murillas, P. Sharma, M. R. Kuehn, M. Oren, C. M. Croce, et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch PNAS, July 3, 2007; 104(27): 11280 - 11285. [Abstract] [Full Text] [PDF]

				R. I. Aqeilan, F. Trapasso, S. Hussain, S. Costinean, D. Marshall, Y. Pekarsky, J. P. Hagan, N. Zanesi, M. Kaou, G. S. Stein, et al. Targeted deletion of Wwox reveals a tumor suppressor function PNAS, March 6, 2007; 104(10): 3949 - 3954. [Abstract] [Full Text] [PDF]

				V. Donati, G. Fontanini, M. Dell'Omodarme, M. C. Prati, S. Nuti, M. Lucchi, A. Mussi, M. Fabbri, F. Basolo, C. M. Croce, et al. WWOX Expression in Different Histologic Types and Subtypes of Non-Small Cell Lung Cancer Clin. Cancer Res., February 1, 2007; 13(3): 884 - 891. [Abstract] [Full Text] [PDF]

				D. Iliopoulos, M. Fabbri, T. Druck, H. R. Qin, S.-Y. Han, and K. Huebner Inhibition of Breast Cancer Cell Growth In vitro and In vivo: Effect of Restoration of Wwox Expression Clin. Cancer Res., January 1, 2007; 13(1): 268 - 274. [Abstract] [Full Text] [PDF]

				E. Gaudio, A. Palamarchuk, T. Palumbo, F. Trapasso, Y. Pekarsky, C. M. Croce, and R. I. Aqeilan Physical Association with WWOX Suppresses c-Jun Transcriptional Activity Cancer Res., December 15, 2006; 66(24): 11585 - 11589. [Abstract] [Full Text] [PDF]

				B. Linggi and G. Carpenter ErbB-4 s80 Intracellular Domain Abrogates ETO2-dependent Transcriptional Repression J. Biol. Chem., September 1, 2006; 281(35): 25373 - 25380. [Abstract] [Full Text] [PDF]

				N.-S. Chang, J. Doherty, A. Ensign, L. Schultz, L.-J. Hsu, and Q. Hong WOX1 Is Essential for Tumor Necrosis Factor-, UV Light-, Staurosporine-, and p53-mediated Cell Death, and Its Tyrosine 33-phosphorylated Form Binds and Stabilizes Serine 46-phosphorylated p53 J. Biol. Chem., December 30, 2005; 280(52): 43100 - 43108. [Abstract] [Full Text] [PDF]

				M. Fabbri, D. Iliopoulos, F. Trapasso, R. I. Aqeilan, A. Cimmino, N. Zanesi, S. Yendamuri, S.-Y. Han, D. Amadori, K. Huebner, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo PNAS, October 25, 2005; 102(43): 15611 - 15616. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal